Clinical Trial Update: A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing Pumitamig to Durvalumab after concurrent chemoradiation in unresectable stage III non-small cell lung cancer is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Pumitamig

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Status: RECRUITING